Stock events for Clearpoint Neuro, Inc. (CLPT)
In the past six months, Clearpoint Neuro's stock has generally trended downwards. Key events impacting the stock price include the acquisition of Irras Holdings Inc. in November 2025. Clearpoint Neuro reported its Q3 2025 results, with revenue of $8.9 million and a 63% gross margin, but the stock fell following the announcement. In January 2026, the company announced preliminary unaudited Q4 2025 revenue of approximately $10.4 million and provided 2026 guidance, which was followed by positive price moves. The President of Clearpoint Neuro notified an intention to sell stock. Clearpoint Neuro announced EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2, expanding access in Europe, which was also followed by positive price moves. B. Riley Financial reduced its price objective for Clearpoint Neuro from $28.00 to $18.00, while maintaining a buy rating, and the stock reached new 52-week lows in early March 2026.
Demand Seasonality affecting Clearpoint Neuro, Inc.’s stock price
The demand for Clearpoint Neuro's products and services appears to be more influenced by factors such as the progression of clinical trials by its biopharma partners, the adoption of its navigation and therapy systems, and the activation of new neurosurgery centers, rather than traditional seasonal consumer patterns. The company's growth can be lumpy due to the nature of its business, which involves long development cycles for therapies and the timing of product launches and regulatory approvals. Clearpoint Neuro is actively expanding its preclinical services and site capacity to meet expected demand as partner programs progress towards commercialization.
Overview of Clearpoint Neuro, Inc.’s business
Clearpoint Neuro, Inc. is a medical technology company specializing in solutions for precise navigation and delivery to the brain and spine, enabling device, cell, and gene therapies. The company develops and commercializes platforms for minimally invasive surgical procedures in the brain and heart, often under direct MRI guidance. Its major products include the ClearPoint Neuro Navigation System, ClearPoint Prism Neuro Laser System, SmartFrame OR, ClearPoint Maestro Brain Model, ClearPoint Array Platform, ClearPoint disposables, and ClearPoint software. The company also provides pre-clinical development services, ClearPoint services, and consulting services. Additionally, through its acquisition of IRRAS Holdings Inc., Clearpoint Neuro now offers the IRRAflow active fluid-exchange system for intracranial fluid management.
CLPT’s Geographic footprint
Clearpoint Neuro is headquartered in Solana Beach, California, United States. The company engages with healthcare and research centers across North America, Europe, Asia, and South America. It has expanded its regulatory approvals for key therapy delivery products to a total of 34 countries worldwide.
CLPT Corporate Image Assessment
Clearpoint Neuro maintains a positive brand reputation, largely driven by its innovative medical technologies and strategic advancements. The company has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2, expanding its access to the latest operating room navigation platform in Europe. It has also secured expanded international regulatory clearances for its therapy delivery products, now totaling 34 countries worldwide. Clearpoint Neuro actively engages in strategic collaborations with industry leaders and prestigious research institutions, enhancing its credibility and potential for innovation. The company is partnered with over 60 biopharma companies, academic centers, and contract research organizations. There have been no explicit reports of significant negative events or controversies directly impacting Clearpoint Neuro's brand reputation in the past year, beyond the general stock price fluctuations.
Ownership
Clearpoint Neuro, Inc. has a diverse ownership structure. Institutional investors hold a significant portion of the company's shares, with 144 institutional owners holding a total of 11,523,727 shares. Individual investors hold a substantial stake, with figures ranging from 51% to 75.31% of the shares. Bruce C. Conway is noted as the largest individual Clearpoint Neuro shareholder, owning 4,000,509 shares, representing 14.07% of the company. Insiders collectively own approximately 3.06% to 6.97% of the stock.
